Subtype
Malignant Colorectal Neoplasm
CI-CAN-00005874Explore in graph →
1,565 active trials21 approved drugs382 evidence items
- NCIt
- C4978
- DOID
- 9256
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005874Explore in graph →
Regulatory
58 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Tucatinib | US FDA | Malignant Colorectal Neoplasm | in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. | approved | Apr 17, 2020 | openfda |
Data updated 19 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Cetuximab | 354 | 54 | 299 |
| Panitumumab | 121 | 29 | 92 |
| Irinotecan | 40 | 8 | 32 |
| Vemurafenib | 30 | 22 | 8 |
| Fluorouracil | 29 | 20 | 9 |
| Dactolisib | 28 | 27 | 1 |
| Chemotherapy | 26 | 8 | 18 |
| Selumetinib | 25 | 24 | 1 |
| Regorafenib Anhydrous | 22 | 6 | 16 |
| Oxaliplatin | 19 | 5 | 14 |
| Aspirin | 17 | 17 | 0 |
| Bevacizumab | 16 | 7 | 9 |
| Trastuzumab |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| 13 |
| 13 |
| 0 |
| Encorafenib | 9 | 8 | 1 |
| Sunitinib | 8 | 1 | 7 |
| Trametinib | 8 | 5 | 3 |
| Lapatinib | 7 | 7 | 0 |
| Dabrafenib | 6 | 4 | 2 |
| Binimetinib | 5 | 4 | 1 |
| Capecitabine | 5 | 2 | 3 |
| Crizotinib | 5 | 5 | 0 |
| Erlotinib | 5 | 3 | 2 |
| Futuximab/Modotuximab Mixture | 5 | 5 | 0 |
| Neratinib | 5 | 5 | 0 |
| Entrectinib | 4 | 3 | 1 |
| Palbociclib | 4 | 4 | 0 |
| Pembrolizumab | 4 | 2 | 2 |
| Pertuzumab | 4 | 4 | 0 |
| Regorafenib | 4 | 3 | 1 |
| Dual IGF-1R/InsR Inhibitor BMS-754807 | 3 | 1 | 2 |
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | 3 | 1 | 2 |
| FOLFOX-4 Regimen | 3 | 0 | 3 |
| Gefitinib | 3 | 2 | 1 |
| Leucovorin | 3 | 3 | 0 |
| Nivolumab | 3 | 1 | 2 |
| PD98059 | 3 | 1 | 2 |
| Sorafenib | 3 | 3 | 0 |
| 5-Fluorouracil/Salicylic Acid Topical Solution | 2 | 0 | 2 |
| 7-Ethyl-10-Hydroxycamptothecin | 2 | 2 | 0 |
| Afatinib | 2 | 2 | 0 |
| Cabozantinib | 2 | 2 | 0 |
| Dasatinib | 2 | 2 | 0 |
| FOLFIRI Regimen | 2 | 2 | 0 |
| Ipilimumab/Nivolumab Regimen | 2 | 2 | 0 |
| Irbesartan | 2 | 2 | 0 |
| Larotrectinib | 2 | 2 | 0 |
| Levoleucovorin | 2 | 1 | 1 |
| Olaparib | 2 | 2 | 0 |
| PD-1 Ligand Inhibitor | 2 | 1 | 1 |
| PLX4720 | 2 | 2 | 0 |
| Sotorasib | 2 | 2 | 0 |
| Therapeutic Tumor Infiltrating Lymphocytes | 2 | 1 | 1 |
| Adagrasib | 1 | 1 | 0 |
| Agerafenib | 1 | 1 | 0 |
| Akt Inhibitor MK2206 | 1 | 1 | 0 |
| Alpelisib | 1 | 1 | 0 |
| Anti-EGFR Monoclonal Antibody | 1 | 0 | 1 |
| Anti-PD1 Monoclonal Antibody | 1 | 1 | 0 |
| Anti-PDL1 Therapy | 1 | 1 | 0 |
| ATR Inhibitor | 1 | 1 | 0 |
| Axitinib | 1 | 1 | 0 |
| Azacitidine | 1 | 1 | 0 |
| B-Raf/VEGFR-2 Inhibitor RAF265 | 1 | 1 | 0 |
| Carfilzomib | 1 | 1 | 0 |
| Ceritinib | 1 | 1 | 0 |
| Cetuximab/Encorafenib Regimen | 1 | 1 | 0 |
| Cetuximab/Irinotecan Regimen | 1 | 0 | 1 |
| Chk1 Inhibitor | 1 | 1 | 0 |
| Cisplatin | 1 | 0 | 1 |
| Cobimetinib | 1 | 1 | 0 |
| Dostarlimab | 1 | 1 | 0 |
| Dovitinib | 1 | 1 | 0 |
| Durvalumab | 1 | 1 | 0 |
| Erdafitinib | 1 | 1 | 0 |
| FOLFIRI-Panitumumab Regimen | 1 | 0 | 1 |
| FOLFOX Regimen | 1 | 1 | 0 |
| G007-LK | 1 | 1 | 0 |
| Ganetespib | 1 | 0 | 1 |
| GDC-0879 | 1 | 1 | 0 |
| Hydroxychloroquine | 1 | 1 | 0 |
| Immune Checkpoint Inhibitor | 1 | 1 | 0 |
| Immunomodulatory Oligonucleotide | 1 | 1 | 0 |
| Infigratinib | 1 | 1 | 0 |
| Ixazomib | 1 | 0 | 1 |
| JW55 | 1 | 1 | 0 |
| Lenvatinib | 1 | 1 | 0 |
| Lestaurtinib | 1 | 1 | 0 |
| Lysine | 1 | 0 | 1 |
| MAP855 | 1 | 1 | 0 |
| MEK Inhibitor RO4987655 | 1 | 1 | 0 |
| Metformin | 1 | 1 | 0 |
| Mirdametinib | 1 | 1 | 0 |
| MTOR Kinase Inhibitor PP242 | 1 | 0 | 1 |
| NOTCH1 Antibody (PF-06293622) | 1 | 1 | 0 |
| Panitumumab Regimen | 1 | 1 | 0 |
| Pan-RAF/MEK Molecular Glue NST-628 | 1 | 1 | 0 |
| Pazopanib | 1 | 1 | 0 |
| PI3K/BET Inhibitor LY294002 | 1 | 1 | 0 |
| Pictilisib | 1 | 1 | 0 |
| Pictilisib Bismesylate | 1 | 1 | 0 |
| Refametinib | 1 | 1 | 0 |
| Rogaratinib | 1 | 1 | 0 |
| SAIT301 | 1 | 1 | 0 |
| Tarextumab | 1 | 1 | 0 |
| Teprotumumab | 1 | 1 | 0 |
| Trastuzumab Deruxtecan | 1 | 1 | 0 |
| Trastuzumab Emtansine | 1 | 1 | 0 |
| Tremelimumab | 1 | 1 | 0 |
| Tucatinib | 1 | 1 | 0 |
| Vorinostat | 1 | 1 | 0 |
| WRN Inhibitor HRO761 | 1 | 1 | 0 |
| WRN Inhibitor RO7589831 | 1 | 1 | 0 |
| WYE354 | 1 | 0 | 1 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.